Global giant licenses maternal health discovery
Clinician-scientist Dr. Isabella Caniggia takes her research personally. Her sister was born with cerebral palsy – related to complications during her mother’s pregnancy known as preeclampsia – and Caniggia has made it her life’s work to unravel the molecular mysteries of this often-devastating condition.
Now, a promising bio-marker discovered by Caniggia and colleagues at Toronto’s Mount Sinai Hospital and The Hospital for Sick Children could point the way to better detection and management of this common maternal condition.
Mount Sinai Hospital has signed a licensing agreement with Inverness Medical Innovations to use the biomarker endoglin to develop diagnostic tools for preeclampsia. The earlier preeclampsia is detected, the better the chances for improved health of both mother and child.
We talked with Dr. Caniggia, Principal Investigator and leading research authority on placental development and preeclampsia at the Samuel Lunenfeld Research Institute of Mount Sinai, about her research:










